CBD for Chronic Radicular Pain on Chronic Opioid Therapy (COT)

Inclusion Criteria: * Males and females aged ≥18 * Diagnosis of radicular CNCP (i.e. lumbar, cervical, thoracic) * Maintained on stable dose opioid therapy for a minimum of 1 month o Note: Morphine Equivalent Daily Dose (MEDD) will be calculated using 2 reference documents: Guideline and conversion table to calculate MEDD from Centers for Medicaid and Medicare Services (CMS); Guidelines from the Centers for Disease Control and Prevention (CDC) intended for calculating total daily dose of opioids for safer dosage of opioid pharmacotherapy * Able to provide voluntary informed consent * If a woman of childbearing potential or a man, are willing to use approved form of contraception from screening for duration of the trial Exclusion Criteria: * Exclusionary medical conditions (e.g., unstable cardiac, hepatic, renal, neurologic illness) or any medical illness that in the opinion of the study physician poses a potential medical danger to the participant * Exclusionary laboratory abnormalities (clinically significant abnormalities of complete blood count or chemistries, significantly impaired liver function) * Current substance use disorder (including Opioid Use Disorder) other than nicotine or caffeine * At screening, a positive urine toxicology test for: amphetamines (AMP), barbiturates (BAR), buprenorphine (BUP), benzodiazepines (BZO), cocaine (COC), 3,4-methylenedioxymethamphetamine (MDMA), methamphetamine (MET), methadone (MTD), phencyclidine (PCP), and tetrahydrocannabinol (THC) * At screening, an alcohol level greater than 0 on a breathalyzer * Severe psychiatric conditions including past or current DSM5 diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder * Current significant suicidality (assessed using the C-SSRS), any suicidal behavior in the past 12 months, or any history of suicide attempts * Current use of recreational or medical cannabis or any product containing CBD * Pregnancy or lactation * Current use of concomitant medications metabolized primarily by CYP2C19 isoenzymes * Current use of concomitant medications significantly or primarily metabolized by CYP3A4 with the potential for adverse drug-drug interactions with CBD (i.e., ketoconazole, rifampicin) * Current use of concomitant medications with a narrow therapeutic window significantly or primarily metabolized by CYP2C9 with the potential for adverse drug-drug interactions with CBD (i.e., warfarin) * Current use of concomitant medications known to have adverse drug-drug interactions with CBD (i.e., valproate) or the potential to cause significant drug-drug interactions (i.e., clobazam). * Known allergy to CBD or any ingredient of the study compound * Currently enrolled in a clinical trial assessing the effects of an anti-pain intervention